{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T07:09:09Z","timestamp":1793862549937,"version":"4.6.1"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100005440","name":"U.S. Department of Health & Human Services | NIH | Center for Scientific Review","doi-asserted-by":"publisher","award":["R01AI155598"],"award-info":[{"award-number":["R01AI155598"]}],"id":[{"id":"10.13039\/100005440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"DOI":"10.1038\/s41541-025-01089-x","type":"journal-article","created":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T09:11:15Z","timestamp":1739956275000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["iDC-targeting PfCSP mRNA vaccine confers superior protection against Plasmodium compared to conventional mRNA"],"prefix":"10.1038","volume":"10","author":[{"given":"Sean","family":"Yanik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varsha","family":"Venkatesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James T.","family":"Gordy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5672-6930","authenticated-orcid":false,"given":"Mohamad-Gabriel","family":"Alameh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Meza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangchen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Glass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yevel","family":"Flores-Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4083-5251","authenticated-orcid":false,"given":"Ying","family":"Tam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nattawat","family":"Chaiyawong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepti","family":"Sarkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drew","family":"Weissman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3527-9147","authenticated-orcid":false,"given":"Richard","family":"Markham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8370-0553","authenticated-orcid":false,"given":"Prakash","family":"Srinivasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,19]]},"reference":[{"key":"1089_CR1","unstructured":"Organization WH. World Malaria Report 2022. https:\/\/www.who.int\/teams\/global-malaria-programme\/reports\/world-malaria-report-2022."},{"key":"1089_CR2","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1128\/CMR.15.4.564-594.2002","volume":"15","author":"R Carter","year":"2002","unstructured":"Carter, R. & Mendis, K. N. Evolutionary and historical aspects of the burden of malaria. Clin. Microbiol Rev. 15, 564\u2013594 (2002).","journal-title":"Clin. Microbiol Rev."},{"key":"1089_CR3","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S0140-6736(19)31567-3","volume":"394","author":"L Schuerman","year":"2019","unstructured":"Schuerman, L. RTS,S malaria vaccine could provide major public health benefits. Lancet 394, 735\u2013736 (2019).","journal-title":"Lancet"},{"key":"1089_CR4","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S0140-6736(23)02511-4","volume":"403","author":"MS Datoo","year":"2024","unstructured":"Datoo, M. S. et al. Safety and efficacy of malaria vaccine candidate R21\/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial. Lancet 403, 533\u2013544 (2024).","journal-title":"Lancet"},{"key":"1089_CR5","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1016\/S1473-3099(22)00442-X","volume":"22","author":"MS Datoo","year":"2022","unstructured":"Datoo, M. S. et al. Efficacy and immunogenicity of R21\/Matrix-M vaccine against clinical malaria after 2 years\u2019 follow-up in children in Burkina Faso: a phase 1\/2b randomised controlled trial. Lancet Infect. Dis. 22, 1728\u20131736 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"1089_CR6","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1093\/milmed\/134.9.1183","volume":"134","author":"J Vanderberg","year":"1969","unstructured":"Vanderberg, J., Nussenzweig, R. & Most, H. Protective immunity produced by the injection of x-irradiated sporozoites of Plasmodium berghei. V. In vitro effects of immune serum on sporozoites. Mil. Med. 134, 1183\u20131190 (1969).","journal-title":"Mil. Med."},{"key":"1089_CR7","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1093\/milmed\/134.9.1176","volume":"134","author":"R Nussenzweig","year":"1969","unstructured":"Nussenzweig, R., Vanderberg, J. & Most, H. Protective immunity produced by the injection of x-irradiated sporozoites of Plasmodium berghei. IV. Dose response, specificity and humoral immunity. Mil. Med. 134, 1176\u20131182 (1969).","journal-title":"Mil. Med."},{"key":"1089_CR8","first-page":"165","volume":"57","author":"RW Gwadz","year":"1979","unstructured":"Gwadz, R. W., Cochrane, A. H., Nussenzweig, V. & Nussenzweig, R. S. Preliminary studies on vaccination of rhesus monkeys with irradiated sporozoites of Plasmodium knowlesi and characterization of surface antigens of these parasites. Bull. World Health Organ 57, 165\u2013173 (1979).","journal-title":"Bull. World Health Organ"},{"key":"1089_CR9","doi-asserted-by":"publisher","first-page":"397","DOI":"10.4269\/ajtmh.1975.24.397","volume":"24","author":"DF Clyde","year":"1975","unstructured":"Clyde, D. F. Immunization of man against falciparum and vivax malaria by use of attenuated sporozoites. Am. J. Trop. Med. Hyg. 24, 397\u2013401 (1975).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"1089_CR10","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1097\/00000441-197312000-00001","volume":"266","author":"DF Clyde","year":"1973","unstructured":"Clyde, D. F., McCarthy, V. C., Miller, R. M. & Hornick, R. B. Specificity of protection of man immunized against sporozoite-induced falciparum malaria. Am. J. Med. Sci. 266, 398\u2013403 (1973).","journal-title":"Am. J. Med. Sci."},{"key":"1089_CR11","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1086\/339409","volume":"185","author":"SL Hoffman","year":"2002","unstructured":"Hoffman, S. L. et al. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J. Infect. Dis. 185, 1155\u20131164 (2002).","journal-title":"J. Infect. Dis."},{"key":"1089_CR12","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1126\/science.1241800","volume":"341","author":"RA Seder","year":"2013","unstructured":"Seder, R. A. et al. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science 341, 1359\u20131365 (2013).","journal-title":"Science"},{"key":"1089_CR13","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/nm.4110","volume":"22","author":"AS Ishizuka","year":"2016","unstructured":"Ishizuka, A. S. et al. Protection against malaria at 1 year and immune correlates following PfSPZ vaccination. Nat. Med. 22, 614\u2013623 (2016).","journal-title":"Nat. Med."},{"key":"1089_CR14","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/0014-4894(73)90022-2","volume":"33","author":"GL Spitalny","year":"1973","unstructured":"Spitalny, G. L. & Nussenzweig, R. S. Plasmodium berghei: relationship between protective immunity and anti-sporozoite (CSP) antibody in mice. Exp. Parasitol. 33, 168\u2013178 (1973).","journal-title":"Exp. Parasitol."},{"key":"1089_CR15","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1038\/nature05361","volume":"444","author":"KA Kumar","year":"2006","unstructured":"Kumar, K. A. et al. The circumsporozoite protein is an immunodominant protective antigen in irradiated sporozoites. Nature 444, 937\u2013940 (2006).","journal-title":"Nature"},{"key":"1089_CR16","doi-asserted-by":"publisher","first-page":"e1005606","DOI":"10.1371\/journal.ppat.1005606","volume":"12","author":"KE Swearingen","year":"2016","unstructured":"Swearingen, K. E. et al. Interrogating the Plasmodium Sporozoite Surface: identification of surface-exposed proteins and demonstration of glycosylation on CSP and TRAP by mass spectrometry-based proteomics. PLoS Pathog. 12, e1005606 (2016).","journal-title":"PLoS Pathog."},{"key":"1089_CR17","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1126\/science.6122269","volume":"215","author":"P Potocnjak","year":"1982","unstructured":"Potocnjak, P., Zavala, F., Nussenzweig, R. & Nussenzweig, V. Inhibition of idiotype-anti-idiotype interaction for detection of a parasite antigen: a new immunoassay. Science 215, 1637\u20131639 (1982).","journal-title":"Science"},{"key":"1089_CR18","doi-asserted-by":"publisher","first-page":"20524","DOI":"10.1074\/jbc.M414254200","volume":"280","author":"D Rathore","year":"2005","unstructured":"Rathore, D. et al. An immunologically cryptic epitope of Plasmodium falciparum circumsporozoite protein facilitates liver cell recognition and induces protective antibodies that block liver cell invasion. J. Biol. Chem. 280, 20524\u201320529 (2005).","journal-title":"J. Biol. Chem."},{"key":"1089_CR19","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/0092-8674(92)90251-7","volume":"70","author":"C Cerami","year":"1992","unstructured":"Cerami, C. et al. The basolateral domain of the hepatocyte plasma membrane bears receptors for the circumsporozoite protein of Plasmodium falciparum sporozoites. Cell 70, 1021\u20131033 (1992).","journal-title":"Cell"},{"key":"1089_CR20","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/385336a0","volume":"385","author":"R M\u00e9nard","year":"1997","unstructured":"M\u00e9nard, R. et al. Circumsporozoite protein is required for development of malaria sporozoites in mosquitoes. Nature 385, 336\u2013340 (1997).","journal-title":"Nature"},{"key":"1089_CR21","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/s41577-019-0209-5","volume":"19","author":"JP Julien","year":"2019","unstructured":"Julien, J. P. & Wardemann, H. Antibodies against Plasmodium falciparum malaria at the molecular level. Nat. Rev. Immunol. 19, 761\u2013775 (2019).","journal-title":"Nat. Rev. Immunol."},{"key":"1089_CR22","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/nm.4512","volume":"24","author":"NK Kisalu","year":"2018","unstructured":"Kisalu, N. K. et al. A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite. Nat. Med. 24, 408\u2013416 (2018).","journal-title":"Nat. Med."},{"key":"1089_CR23","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1172\/JCI70349","volume":"124","author":"L Foquet","year":"2014","unstructured":"Foquet, L. et al. Vaccine-induced monoclonal antibodies targeting circumsporozoite protein prevent Plasmodium falciparum infection. J. Clin. Investig. 124, 140\u2013144 (2014).","journal-title":"J. Clin. Investig."},{"key":"1089_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-014-0117-2","volume":"12","author":"MT White","year":"2014","unstructured":"White, M. T. et al. A combined analysis of immunogenicity, antibody kinetics and vaccine efficacy from phase 2 trials of the RTS,S malaria vaccine. BMC Med. 12, 117 (2014).","journal-title":"BMC Med."},{"key":"1089_CR25","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1172\/JCI156588","volume":"132","author":"F Zavala","year":"2022","unstructured":"Zavala, F. RTS, S: the first malaria vaccine. J Clin Investig. 132, 7\u20139 (2022).","journal-title":"J Clin Investig."},{"key":"1089_CR26","doi-asserted-by":"publisher","first-page":"e90413","DOI":"10.1371\/journal.pone.0090413","volume":"9","author":"K Luo","year":"2014","unstructured":"Luo, K. et al. Fusion of antigen to a dendritic cell targeting chemokine combined with adjuvant yields a malaria DNA vaccine with enhanced protective capabilities. PLoS ONE 9, e90413 (2014).","journal-title":"PLoS ONE"},{"key":"1089_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05041-7","volume":"9","author":"A Baeza Garcia","year":"2018","unstructured":"Baeza Garcia, A. et al. Neutralization of the Plasmodium-encoded MIF ortholog confers protective immunity against malaria infection. Nat. Commun. 9, 2714 (2018).","journal-title":"Nat. Commun."},{"key":"1089_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-021-00345-0","volume":"6","author":"KL Mallory","year":"2021","unstructured":"Mallory, K. L. et al. Messenger RNA expressing PfCSP induces functional, protective immune responses against malaria in mice. NPJ Vaccines 6, 84 (2021).","journal-title":"NPJ Vaccines"},{"key":"1089_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-022-00577-8","volume":"7","author":"CTH Hayashi","year":"2022","unstructured":"Hayashi, C. T. H. et al. mRNA-LNP expressing PfCSP and Pfs25 vaccine candidates targeting infection and transmission of Plasmodium falciparum. NPJ Vaccines 7, 155 (2022).","journal-title":"NPJ Vaccines"},{"key":"1089_CR30","doi-asserted-by":"publisher","first-page":"64","DOI":"10.4049\/jimmunol.180.1.64","volume":"180","author":"IA Cockburn","year":"2008","unstructured":"Cockburn, I. A., Chakravarty, S., Overstreet, M. G., Garc\u00eda-Sastre, A. & Zavala, F. Memory CD8+ T cell responses expand when antigen presentation overcomes T cell self-regulation. J. Immunol. 180, 64\u201371 (2008).","journal-title":"J. Immunol."},{"key":"1089_CR31","doi-asserted-by":"publisher","first-page":"e1000877","DOI":"10.1371\/journal.ppat.1000877","volume":"6","author":"IA Cockburn","year":"2010","unstructured":"Cockburn, I. A. et al. Prolonged antigen presentation is required for optimal CD8+ T cell responses against malaria liver stage parasites. PLoS Pathog. 6, e1000877 (2010).","journal-title":"PLoS Pathog."},{"key":"1089_CR32","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/S1471-4922(02)00053-3","volume":"19","author":"M Tsuji","year":"2003","unstructured":"Tsuji, M. & Zavala, F. T cells as mediators of protective immunity against liver stages of Plasmodium. Trends Parasitol. 19, 88\u201393 (2003).","journal-title":"Trends Parasitol."},{"key":"1089_CR33","doi-asserted-by":"publisher","first-page":"14017","DOI":"10.1073\/pnas.0805452105","volume":"105","author":"NW Schmidt","year":"2008","unstructured":"Schmidt, N. W. et al. Memory CD8 T cell responses exceeding a large but definable threshold provide long-term immunity to malaria. Proc. Natl Acad. Sci. USA 105, 14017\u201314022 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1089_CR34","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1084\/jem.20190301","volume":"216","author":"DL Hill","year":"2019","unstructured":"Hill, D. L. et al. The adjuvant GLA-SE promotes human Tfh cell expansion and emergence of public TCR\u03b2 clonotypes. J. Exp. Med. 216, 1857\u20131873 (2019).","journal-title":"J. Exp. Med."},{"key":"1089_CR35","doi-asserted-by":"publisher","first-page":"e66","DOI":"10.1038\/cti.2016.6","volume":"5","author":"C Macri","year":"2016","unstructured":"Macri, C., Dumont, C., Johnston, A. P. & Mintern, J. D. Targeting dendritic cells: a promising strategy to improve vaccine effectiveness. Clin. Transl. Immunol. 5, e66 (2016).","journal-title":"Clin. Transl. Immunol."},{"key":"1089_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2023.101762","volume":"68","author":"C Macri","year":"2023","unstructured":"Macri, C., Jenika, D., Ouslinis, C. & Mintern, J. D. Targeting dendritic cells to advance cross-presentation and vaccination outcomes. Semin. Immunol. 68, 101762 (2023).","journal-title":"Semin. Immunol."},{"key":"1089_CR37","doi-asserted-by":"publisher","first-page":"e11021","DOI":"10.1371\/journal.pone.0011021","volume":"5","author":"PT Loudon","year":"2010","unstructured":"Loudon, P. T. et al. GM-CSF increases mucosal and systemic immunogenicity of an H1N1 influenza DNA vaccine administered into the epidermis of non-human primates. PLoS ONE 5, e11021 (2010).","journal-title":"PLoS ONE"},{"key":"1089_CR38","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s12934-015-0360-z","volume":"14","author":"K Kuczkowska","year":"2015","unstructured":"Kuczkowska, K., Mathiesen, G., Eijsink, V. G. & \u00d8ynebr\u00e5ten, I. Lactobacillus plantarum displaying CCL3 chemokine in fusion with HIV-1 Gag derived antigen causes increased recruitment of T cells. Micro. Cell Fact. 14, 169 (2015).","journal-title":"Micro. Cell Fact."},{"key":"1089_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-79427-3","volume":"11","author":"K Luo","year":"2021","unstructured":"Luo, K., Gordy, J. T., Zavala, F. & Markham, R. B. A chemokine-fusion vaccine targeting immature dendritic cells elicits elevated antibody responses to malaria sporozoites in infant macaques. Sci. Rep. 11, 1220 (2021).","journal-title":"Sci. Rep."},{"key":"1089_CR40","doi-asserted-by":"publisher","first-page":"14893","DOI":"10.1074\/jbc.272.23.14893","volume":"272","author":"M Baba","year":"1997","unstructured":"Baba, M. et al. Identification of CCR6, the specific receptor for a novel lymphocyte-directed CC chemokine LARC. J. Biol. Chem. 272, 14893\u201314898 (1997).","journal-title":"J. Biol. Chem."},{"key":"1089_CR41","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1097\/00007890-200201151-00005","volume":"73","author":"C Caux","year":"2002","unstructured":"Caux, C. et al. Regulation of dendritic cell recruitment by chemokines. Transplantation 73, S7\u2013S11 (2002).","journal-title":"Transplantation"},{"key":"1089_CR42","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1189\/jlb.0708420","volume":"84","author":"S He","year":"2008","unstructured":"He, S., Cao, Q., Yoneyama, H., Ge, H. & Zhang, Y. MIP-3alpha and MIP-1alpha rapidly mobilize dendritic cell precursors into the peripheral blood. J. Leukoc. Biol. 84, 1549\u20131556 (2008).","journal-title":"J. Leukoc. Biol."},{"key":"1089_CR43","doi-asserted-by":"publisher","first-page":"8391","DOI":"10.4049\/jimmunol.181.12.8391","volume":"181","author":"T Yamazaki","year":"2008","unstructured":"Yamazaki, T. et al. CCR6 regulates the migration of inflammatory and regulatory T cells. J. Immunol. 181, 8391\u20138401 (2008).","journal-title":"J. Immunol."},{"key":"1089_CR44","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1172\/JCI200419762","volume":"113","author":"K Furumoto","year":"2004","unstructured":"Furumoto, K., Soares, L., Engleman, E. G. & Merad, M. Induction of potent antitumor immunity by in situ targeting of intratumoral DCs. J. Clin. Investig. 113, 774\u2013783 (2004).","journal-title":"J. Clin. Investig."},{"key":"1089_CR45","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s00262-019-02471-0","volume":"69","author":"JT Gordy","year":"2020","unstructured":"Gordy, J. T. et al. Treatment with an immature dendritic cell-targeting vaccine supplemented with IFN-\u03b1 and an inhibitor of DNA methylation markedly enhances survival in a murine melanoma model. Cancer Immunol. Immunother. 69, 569\u2013580 (2020).","journal-title":"Cancer Immunol. Immunother."},{"key":"1089_CR46","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1038\/mt.sj.6300129","volume":"15","author":"R Song","year":"2007","unstructured":"Song, R., Liu, S. & Leong, K. W. Effects of MIP-1 alpha, MIP-3 alpha, and MIP-3 beta on the induction of HIV Gag-specific immune response with DNA vaccines. Mol. Ther. 15, 1007\u20131015 (2007).","journal-title":"Mol. Ther."},{"key":"1089_CR47","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1182\/blood-2004-02-0637","volume":"104","author":"A Biragyn","year":"2004","unstructured":"Biragyn, A. et al. Chemokine receptor-mediated delivery directs self-tumor antigen efficiently into the class II processing pathway in vitro and induces protective immunity in vivo. Blood 104, 1961\u20131969 (2004).","journal-title":"Blood"},{"key":"1089_CR48","doi-asserted-by":"publisher","first-page":"4597","DOI":"10.1182\/blood-2005-08-3207","volume":"107","author":"R Schiavo","year":"2006","unstructured":"Schiavo, R. et al. Chemokine receptor targeting efficiently directs antigens to MHC class I pathways and elicits antigen-specific CD8+ T-cell responses. Blood 107, 4597\u20134605 (2006).","journal-title":"Blood"},{"key":"1089_CR49","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1016\/j.vaccine.2017.03.052","volume":"35","author":"K Luo","year":"2017","unstructured":"Luo, K., Zavala, F., Gordy, J., Zhang, H. & Markham, R. B. Extended protection capabilities of an immature dendritic-cell targeting malaria sporozoite vaccine. Vaccine 35, 2358\u201364 (2017).","journal-title":"Vaccine"},{"key":"1089_CR50","doi-asserted-by":"crossref","unstructured":"Shafaati, M. et al. A brief review on DNA vaccines in the era of COVID-19. Future Virol. 17, 49\u201366 (2021).","DOI":"10.2217\/fvl-2021-0170"},{"key":"1089_CR51","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.imlet.2017.07.007","volume":"190","author":"Y Kou","year":"2017","unstructured":"Kou, Y. et al. Tissue plasminogen activator (tPA) signal sequence enhances immunogenicity of MVA-based vaccine against tuberculosis. Immunol. Lett. 190, 51\u201357 (2017).","journal-title":"Immunol. Lett."},{"key":"1089_CR52","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/j.ymthe.2020.04.018","volume":"28","author":"AW Freyn","year":"2020","unstructured":"Freyn, A. W. et al. A multi-targeting, nucleoside-modified mRNA influenza virus vaccine provides broad protection in mice. Mol. Ther. 28, 1569\u20131584 (2020).","journal-title":"Mol. Ther."},{"key":"1089_CR53","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.omtn.2019.02.018","volume":"15","author":"M Baiersd\u00f6rfer","year":"2019","unstructured":"Baiersd\u00f6rfer, M. et al. A facile method for the removal of dsRNA contaminant from in vitro-transcribed mRNA. Mol. Ther. Nucleic Acids 15, 26\u201335 (2019).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"1089_CR54","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1038\/mt.2013.124","volume":"21","author":"MA Maier","year":"2013","unstructured":"Maier, M. A. et al. Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics. Mol. Ther. 21, 1570\u20131578 (2013).","journal-title":"Mol. Ther."},{"key":"1089_CR55","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s41541-024-00819-x","volume":"9","author":"E Locke","year":"2024","unstructured":"Locke, E. et al. Establishing RTS,S\/AS01 as a benchmark for comparison to next-generation malaria vaccines in a mouse model. NPJ Vaccine. 9, 29 (2024).","journal-title":"NPJ Vaccine."},{"key":"1089_CR56","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-019-3055-9","volume":"18","author":"Y Flores-Garcia","year":"2019","unstructured":"Flores-Garcia, Y. et al. Optimization of an in vivo model to study immunity to Plasmodium falciparum pre-erythrocytic stages. Malar. J. 18, 426 (2019).","journal-title":"Malar. J."},{"key":"1089_CR57","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.vaccine.2007.10.064","volume":"26","author":"K Miura","year":"2008","unstructured":"Miura, K. et al. Development and characterization of a standardized ELISA including a reference serum on each plate to detect antibodies induced by experimental malaria vaccines. Vaccine 26, 193\u2013200 (2008).","journal-title":"Vaccine"},{"key":"1089_CR58","doi-asserted-by":"publisher","first-page":"2882","DOI":"10.1128\/IAI.00461-13","volume":"81","author":"DA Espinosa","year":"2013","unstructured":"Espinosa, D. A. et al. Development of a chimeric Plasmodium berghei strain expressing the repeat region of the P. vivax circumsporozoite protein for in vivo evaluation of vaccine efficacy. Infect. Immun. 81, 2882\u20132887 (2013).","journal-title":"Infect. Immun."},{"key":"1089_CR59","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1016\/j.immuni.2021.11.001","volume":"54","author":"MG Alameh","year":"2021","unstructured":"Alameh, M. G. et al. Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses. Immunity 54, 2877\u201392.e7 (2021).","journal-title":"Immunity"},{"key":"1089_CR60","doi-asserted-by":"publisher","first-page":"e0128714","DOI":"10.1371\/journal.pone.0128714","volume":"10","author":"A Boyd","year":"2015","unstructured":"Boyd, A. et al. Pathogen-specific T cell polyfunctionality is a correlate of T cell efficacy and immune protection. PLoS ONE 10, e0128714 (2015).","journal-title":"PLoS ONE"},{"key":"1089_CR61","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1073\/pnas.1117194109","volume":"109","author":"Q Han","year":"2012","unstructured":"Han, Q. et al. Polyfunctional responses by human T cells result from sequential release of cytokines. Proc. Natl Acad. Sci. USA 109, 1607\u20131612 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1089_CR62","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1073\/pnas.1119856109","volume":"109","author":"WN Haining","year":"2012","unstructured":"Haining, W. N. Travels in time: assessing the functional complexity of T cells. Proc. Natl Acad. Sci. USA 109, 1359\u20131360 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1089_CR63","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/nm1592","volume":"13","author":"PA Darrah","year":"2007","unstructured":"Darrah, P. A. et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat. Med. 13, 843\u2013850 (2007).","journal-title":"Nat. Med."},{"key":"1089_CR64","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/nbt.3187","volume":"33","author":"L Lin","year":"2015","unstructured":"Lin, L. et al. COMPASS identifies T-cell subsets correlated with clinical outcomes. Nat. Biotechnol. 33, 610\u2013616 (2015).","journal-title":"Nat. Biotechnol."},{"key":"1089_CR65","doi-asserted-by":"publisher","first-page":"8047","DOI":"10.4049\/jimmunol.0801592","volume":"182","author":"T Lindenstr\u00f8m","year":"2009","unstructured":"Lindenstr\u00f8m, T. et al. Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells. J. Immunol. 182, 8047\u20138055 (2009).","journal-title":"J. Immunol."},{"key":"1089_CR66","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.3389\/fimmu.2017.01008","volume":"8","author":"G Moncunill","year":"2017","unstructured":"Moncunill, G. et al. RTS,S\/AS01E malaria vaccine induces memory and polyfunctional T cell responses in a pediatric African Phase III Trial. Front. Immunol. 8, 1008 (2017).","journal-title":"Front. Immunol."},{"key":"1089_CR67","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.87499","volume":"2","author":"JG Burel","year":"2017","unstructured":"Burel, J. G., Apte, S. H., Groves, P. L., McCarthy, J. S. & Doolan, D. L. Polyfunctional and IFN. JCI Insight 2, e87499 (2017).","journal-title":"JCI Insight"},{"key":"1089_CR68","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1038\/s41591-020-0881-9","volume":"26","author":"R Murugan","year":"2020","unstructured":"Murugan, R. et al. Evolution of protective human antibodies against Plasmodium falciparum circumsporozoite protein repeat motifs. Nat. Med. 26, 1135\u20131145 (2020).","journal-title":"Nat. Med."},{"key":"1089_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21221-4","volume":"12","author":"T Pholcharee","year":"2021","unstructured":"Pholcharee, T. et al. Structural and biophysical correlation of anti-NANP antibodies with in vivo protection against P. falciparum. Nat. Commun. 12, 1063 (2021).","journal-title":"Nat. Commun."},{"key":"1089_CR70","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00714-x","volume":"8","author":"CJ Genito","year":"2023","unstructured":"Genito, C. J. et al. Protective antibody threshold of RTS,S\/AS01 malaria vaccine correlates antigen and adjuvant dose in mouse model. NPJ Vaccines 8, 114 (2023).","journal-title":"NPJ Vaccines"},{"key":"1089_CR71","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10195-z","volume":"10","author":"C Doba\u00f1o","year":"2019","unstructured":"Doba\u00f1o, C. et al. Concentration and avidity of antibodies to different circumsporozoite epitopes correlate with RTS,S\/AS01E malaria vaccine efficacy. Nat. Commun. 10, 2174 (2019).","journal-title":"Nat. Commun."},{"key":"1089_CR72","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1016\/S1473-3099(15)00239-X","volume":"15","author":"MT White","year":"2015","unstructured":"White, M. T. et al. Immunogenicity of the RTS,S\/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial. Lancet Infect. Dis. 15, 1450\u20131458 (2015).","journal-title":"Lancet Infect. Dis."},{"key":"1089_CR73","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(15)60721-8","volume":"386","author":"RTS SCTP.","year":"2015","unstructured":"RTS SCTP. Efficacy and safety of RTS,S\/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 386, 31\u201345 (2015).","journal-title":"Lancet"},{"key":"1089_CR74","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1056\/NEJMoa2101746","volume":"385","author":"B Balikagala","year":"2021","unstructured":"Balikagala, B. et al. Evidence of Artemisinin-resistant malaria in Africa. N. Engl. J. Med, 385, 1163\u20131171 (2021).","journal-title":"N. Engl. J. Med,"},{"key":"1089_CR75","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1016\/S0140-6736(20)31522-1","volume":"396","author":"A Ezeh","year":"2020","unstructured":"Ezeh, A., Kissling, F. & Singer, P. Why sub-Saharan Africa might exceed its projected population size by 2100. Lancet 396, 1131\u20131133 (2020).","journal-title":"Lancet"},{"key":"1089_CR76","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1084\/jem.192.5.705","volume":"192","author":"MC Dieu-Nosjean","year":"2000","unstructured":"Dieu-Nosjean, M. C. et al. Macrophage inflammatory protein 3alpha is expressed at inflamed epithelial surfaces and is the most potent chemokine known in attracting Langerhans cell precursors. J. Exp. Med. 192, 705\u2013718 (2000).","journal-title":"J. Exp. Med."},{"key":"1089_CR77","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/nri2274","volume":"8","author":"RA Seder","year":"2008","unstructured":"Seder, R. A., Darrah, P. A. & Roederer, M. T-cell quality in memory and protection: implications for vaccine design. Nat. Rev. Immunol. 8, 247\u2013258 (2008).","journal-title":"Nat. Rev. Immunol."},{"key":"1089_CR78","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1073\/pnas.1621489114","volume":"114","author":"D Kazmin","year":"2017","unstructured":"Kazmin, D. et al. Systems analysis of protective immune responses to RTS, S malaria vaccination in humans. Proc. Natl Acad. Sci. USA 114, 2425\u20132430 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01089-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01089-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01089-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T09:11:24Z","timestamp":1739956284000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01089-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,19]]},"references-count":78,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1089"],"URL":"https:\/\/doi.org\/10.1038\/s41541-025-01089-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4656309\/v1","asserted-by":"object"}]},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,19]]},"assertion":[{"value":"28 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.W. is named on patents describing the use of nucleoside-modified mRNA - lipid nanoparticle vaccines. Y.T. is an employee of Acuitas Therapeutics that is involved in the development of mRNA-LNP therapeutics. D.W. and M.-G.A. are listed as inventors on patents covering LNP for nucleic acid therapeutic delivery for vaccines. Y.S., V.V., J.T.G., J.M., Y.L., E.G., Y. F-G., N.C., D.S., R.M, and P.S. have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"34"}}